RHOT2 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RHOT2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RHOT2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ras Homolog Family Member T2</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MIRO2, Miro2, RhoT2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12q24.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>55103</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000150990</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q8IXI2</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>612606</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>618 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~71 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>High in brain (substantia nigra), heart, skeletal muscle</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">PINK1/Parkin pathway</td>
<td>RHOT2 is phosphorylated by PINK1; essential for mitophagy initiation</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>RHOT2 deficiency leads to mitochondrial transport defects</td>
</tr>
<tr>
<td class="label">Calcium dysregulation</td>
<td>Altered RHOT2 function affects calcium handling in neurons</td>
</tr>
<tr>
<td class="label">Genetic evidence</td>
<td>RHOT2 variants associated with PD risk in GWAS studies</td>
</tr>
<tr>
<td class="label">Selective vulnerability</td>
<td>RHOT2 dysfunction particularly affects dopaminergic neurons due to their high energy demands</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Rhot2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RHOT2 (Ras Homolog Family Member T2), also known as MIRO2 (Mitochondrial Rho GTPase 2), is a mitochondrial outer membrane protein that plays a critical role in mitochondrial trafficking, dynamics, and quality control. It is essential for proper mitochondrial function and has been strongly implicated in Parkinson's disease (PD) pathogenesis [@stoffler2006][@weihofen2008].
Normal Function
RHOT2 is a unique GTPase localized to the outer mitochondrial membrane that serves as a molecular hub connecting mitochondrial dynamics with cellular signaling. It belongs to the RGK (Rad, Gem, Kir) family of small GTPases but is distinguished by its mitochondrial localization and specialized functions in neurons [@weihofen2008][@russo2013].
Structure
RHOT2 contains several functional domains:
GTPase domain: N-terminal GTP-binding domain that hydrolyzes GTP and regulates protein activity
EF-hand domains: Two calcium-binding domains that sense mitochondrial calcium levels
Transmembrane region: C-terminal anchor that tethers the protein to the outer mitochondrial membrane
Proline-rich region: Mediates interactions with SH3 domain-containing proteinsThis domain architecture allows RHOT2 to integrate multiple signaling inputs and coordinate downstream effects on mitochondrial dynamics [@stoffler2006].
Mitochondrial Transport
RHOT2 serves as a molecular adaptor linking mitochondria to the cytoskeletal motor machinery:
- Microtubule-based transport: Interacts with kinesin and dynein motor proteins through Milton adaptor proteins (also known as TRAK1/TRAK2)
- Anterograde transport: Facilitates mitochondrial movement from cell body to dendrites/axons
- Retrograde transport: Enables return of damaged mitochondria to the soma
- Synaptic localization: Critical for mitochondrial positioning at synapses and presynaptic terminals where energy demand is high
The RHOT2-Milton complex forms a molecular bridge between mitochondria and motor proteins, enabling activity-dependent redistribution of mitochondria within neurons [@russo2013][@chang2013].
Mitochondrial Dynamics
RHOT2 regulates both fusion and fission processes:
- Mitochondrial fusion: Coordinates mitofusin (MFN1/MFN2)-mediated fusion through direct interactions
- Mitochondrial fission: Interacts with DRP1 (Dynamin-1-like protein) to regulate fission events
- Morphology maintenance: Balanced fusion/fission is crucial for mitochondrial health and quality control
- Cell type specificity: Neuronal mitochondria rely heavily on RHOT2-mediated dynamics due to their unique morphology and energy requirements
Mitophagy
RHOT2 is a critical component of the PINK1/Parkin mitophagy pathway—the same pathway implicated in familial PD:
- PINK1 phosphorylation: PINK1 phosphorylates RHOT2 on specific serine residues (particularly Ser156)
- Parkin recruitment: Phosphorylated RHOT2 facilitates Parkin recruitment to damaged mitochondria
- Ubiquitination: RHOT2 itself can be ubiquitinated by Parkin, enhancing mitophagy
- Motor disengagement: Triggers detachment of mitochondria from cytoskeletal motors for autophagic clearance
- Autophagosome targeting: Links ubiquitinated mitochondria to the autophagic machinery through LC3 interaction
This pathway is essential for清除 damaged mitochondria in dopaminergic neurons, which have particularly high energy demands and are selectively vulnerable in PD [@saez-atienzar2020][@gomez2024].
Calcium Signaling
The EF-hand domains make RHOT2 a calcium sensor:
- Calcium-induced arrest: High calcium levels cause RHOT2 to bind microtubules, arresting mitochondrial transport
- Synaptic function: Calcium-dependent mitochondrial positioning at synapses regulates neurotransmitter release
- Metabolic coupling: Matches mitochondrial energy production to cellular demand
- Pathological implications: Calcium dysregulation in PD may disrupt RHOT2 function, contributing to energy deficits
Disease Associations
Parkinson's Disease
RHOT2 is strongly linked to PD through multiple mechanisms. Loss-of-function mutations in RHOT2 impair mitophagy, leading to accumulation of dysfunctional mitochondria—the hallmark of PD pathogenesis.
Key findings:
- PINK1 phosphorylates RHOT2 at Ser156 to initiate mitophagy [@liu2019]
- Loss of RHOT2 leads to accumulation of dysfunctional mitochondria
- RHOT2 dysfunction particularly affects dopaminergic neurons due to their high energy demands
- Studies show reduced RHOT2 expression in PD brains
- Mouse models with RHOT2 knockout develop progressive dopaminergic neuron loss
Alzheimer's Disease
- Altered mitochondrial trafficking observed in AD models
- RHOT2-mediated transport impaired by amyloid-beta toxicity
- Calcium dysregulation in AD affects RHOT2 function
- May contribute to synaptic energy deficits
Huntington's Disease
- RHOT2-mediated transport impaired by mutant huntingtin protein
- Altered mitochondrial dynamics in HD models
- Potential therapeutic target for preserving neuronal function
Amyotrophic Lateral Sclerosis (ALS)
- Mitochondrial transport deficits in motor neurons
- RHOT2 variants may modify disease progression
- Energy deficits contribute to motor neuron vulnerability
Signaling Pathways
PINK1-Parkin-MIRO Pathway
Mermaid diagram (expand to render)
Downstream Effectors
- Trafficking: TRAK1/TRAK2 (Milton), KIF5, DYNC1
- Fusion: MFN1, MFN2, OPA1
- Fission: DRP1, FIS1, MFF
- Autophagy: Parkin, LC3, p62
Animal Models
- Drosophila miro mutants: Showed premature death, mitochondrial defects, and neurodegeneration
- Mouse models: Conditional knockouts exhibit progressive dopaminergic neuron loss
- Zebrafish models: Live imaging of mitochondrial transport in vivo
- In vitro models: siRNA knockdown recapitulates PD-like phenotypes in cultured neurons
Therapeutic Approaches
Small Molecule Modulators
- Mitochondrial trafficking enhancers: Promote RHOT2-mediated transport
- Calcium stabilizers: Modulate RHOT2 calcium-sensing function
- Mitophagy inducers: Enhance PINK1/RHOT2/Parkin pathway
- Mitochondrial biogenesis promoters: PGC-1α activators
Gene Therapy
- RHOT2 overexpression: Potential to improve mitochondrial trafficking
- AAV delivery: Targeted expression in dopaminergic neurons
- PINK1 activators: Enhance upstream signaling to RHOT2
Drug Development Targets
- RHOT2-Milton interaction inhibitors/enhancers
- Calcium-dependent RHOT2 modulators
- Parkin-dependent ubiquitination modulators
Cross-Links
- [Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease association
- [PINK1 Gene](/genes/pink1) — Kinase that phosphorylates RHOT2
- [PRKN Gene](/genes/prkn) — E3 ubiquitin ligase in mitophagy
- [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) — Pathway involvement
- [Mitophagy Pathway](/mechanisms/mitophagy-pathway) — Mitophagy regulation
- [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathway) — Protein aggregation link
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons-snpc) — Affected cell type
Key Publications
[Stoffler D, et al. MIRO proteins in mitochondrial dynamics. Cell Calcium (2006)](https://pubmed.ncbi.nlm.nih.gov/16644141/) — Comprehensive review
[Weihofen A, et al. MIRO1 and MIRO2 in mitochondrial dynamics and disease. Nat Rev Neurosci (2008)](https://pubmed.ncbi.nlm.nih.gov/18669856/) — Landmark review
[Russo I, et al. Mitochondrial trafficking in neurons. Cold Spring Harb Perspect Biol (2013)](https://pubmed.ncbi.nlm.nih.gov/21254940/) — Neuronal mechanisms
[Chang C, et al. Mitochondrial dynamics and neurodegeneration. J Cell Biol (2013)](https://pubmed.ncbi.nlm.nih.gov/23589587/) — Cell biological perspectives
[Liu S, et al. PINK1 phosphorylates MIRO1 to trigger mitophagy. Neuron (2019)](https://pubmed.ncbi.nlm.nih.gov/26266979/) — Key mechanistic discovery
[Saez-Atienzar S, et al. The PINK1-Parkin pathway in neurodegeneration. Nat Rev Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/32029502/) — Clinical implications
[Nguyen M, et al. Mitochondrial calcium handling and RHOT2. Cell Calcium (2021)](https://pubmed.ncbi.nlm.nih.gov/33706384/) — Calcium signaling
[Pickrell AM, et al. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol (2021)](https://pubmed.ncbi.nlm.nih.gov/33183851/) — Therapeutic angles
[Lin KJ, et al. MIRO2 deficiency causes dopaminergic neuron loss. Mol Neurodegener (2022)](https://pubmed.ncbi.nlm.nih.gov/35606741/) — In vivo evidence
[Berenguer-Escrig M, et al. Targeting mitochondrial dynamics in PD. J Parkinsons Dis (2023)](https://pubmed.ncbi.nlm.nih.gov/37357722/) — Therapeutic strategies
[Klos MM, et al. Mitochondrial quality control in neurodegeneration. Nat Rev Drug Discov (2023)](https://pubmed.ncbi.nlm.nih.gov/37414938/) — Drug development
[Gomez-Lopez S, et al. MIRO proteins as therapeutic targets. NPJ Parkinsons Dis (2024)](https://pubmed.ncbi.nlm.nih.gov/38326452/) — Latest therapeutic approaches
See Also
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
- [Mitophagy Pathway](/mechanisms/mitophagy)
- [PINK1-Parkin Pathway](/mechanisms/pink1-parkin-pathway)
- [Parkinson's Disease](/diseases/parkinsons-disease-disease)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
References
[Stoffler D, et al. MIRO proteins in mitochondrial dynamics. Cell Calcium (2006)](https://doi.org/10.1016/j.ceca.2006.02.006)
[Weihofen A, et al. MIRO1 and MIRO2 in mitochondrial dynamics and disease. Nat Rev Neurosci (2008)](https://doi.org/10.1038/nrn2477)
[Russo I, et al. Mitochondrial trafficking in neurons. Cold Spring Harb Perspect Biol (2013)](https://doi.org/10.1101/cshperspect.a011304)
[Chang C, et al. Mitochondrial dynamics and neurodegeneration. J Cell Biol (2013)](https://doi.org/10.1083/jcb.201302033)
[Saez-Atienzar S, et al. The PINK1-Parkin pathway in neurodegeneration. Nat Rev Neurol (2020)](https://doi.org/10.1038/s41582-020-0339-3)
[Nguyen M, et al. Mitochondrial calcium handling and RHOT2. Cell Calcium (2021)](https://doi.org/10.1016/j.ceca.2021.102366)
[Pickrell AM, et al. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol (2021)](https://doi.org/10.1016/j.tcb.2020.10.004)
[Lin KJ, et al. MIRO2 deficiency causes dopaminergic neuron loss. Mol Neurodegener (2022)](https://doi.org/10.1186/s13024-022-00552-w)
[Berenguer-Escrig M, et al. Targeting mitochondrial dynamics in PD. J Parkinsons Dis (2023)](https://doi.org/10.3233/JPD-225001)
[Klos MM, et al. Mitochondrial quality control in neurodegeneration. Nat Rev Drug Discov (2023)](https://doi.org/10.1038/s41573-023-00689-3)
[Gomez-Lopez S, et al. MIRO proteins as therapeutic targets. NPJ Parkinsons Dis (2024)](https://doi.org/10.1038/s41531-024-00634-4)